Abstract
Purpose
To evaluate the early efficacy and safety of intrastromal injection of teicoplanin as the alternative treatment for the methicillin-resistant Staphylococcus aureus (MRSA) keratitis by comparing it with vancomycin.
Materials and methods
Twenty-four eyes of 24 New Zealand white rabbits were included in the study. MRSA keratitis was induced in the right eye of each rabbit by injecting 0.1 mL MRSA suspension containing 1000 colony-forming units (CFU) intrastromally to the central cornea. The rabbits were divided into three treatment groups 24 h after the inoculation of MRSA. Eight rabbits received intrastromal teicoplanin therapy, eight received intrastromal vancomycin therapy, and eight received balanced salt solution and served as the control group. Nine hours after the treatment, all rabbits were sacrificed and corneal tissues were collected for microbiological analysis. We also examined and scored all the rabbits clinically before and after the treatment.
Results
The control group scored higher with regard to conjunctival injection, iritis, fibrin, hypopyon, epithelial erosion, and corneal infiltrate than the vancomycin and teicoplanin groups (p = 0.031, 0.010, < 0.001, 0.029, 0.009, and < 0.001, respectively). Chemosis and corneal oedema were similar in all groups (p = 0.731 and 0.075, respectively). The severity of all clinical parameters was similar in both the vancomycin and teicoplanin groups after the treatment. The bacterial load was the highest (7.83 ± 0.71 log10 CFU/g) in the control group. The eyes treated with vancomycin and teicoplanin had similar bacterial loads (6.40 ± 0.69 vs. 6.31 ± 0.75 log10 CFU/g, p = 0.809).
Conclusion
The efficiency of teicoplanin seems to be comparable to that of vancomycin when administered intrastromally in the early treatment of MRSA keratitis. The former may be preferred in the treatment of selected cases with vancomycin hypersensitivity or resistance.
Similar content being viewed by others
Availability of data and materials
Not applicable.
References
Egrilmez S, Yildirim-Theveny S (2020) Treatment-resistant bacterial keratitis: challenges and solutions. Clin Ophthalmol 14:287–297
Durrani AF, Atta S, Bhat A et al (2020) Methicillin-resistant Staphylococcal aureus keratitis: initial treatment, risk factors, clinical features, and treatment outcomes. Am J Ophthalmol 214:119–126
Robaei D, Carnt N, Watson S (2016) Established and emerging ancillary techniques in management of microbial keratitis: a review. Br J Ophthalmol 100(9):1163–1170
Romanowski EG, Romanowski JE, Shanks RMQ et al (2020) Topical vancomycin 5% is more efficacious than 2.5% and 1.25% for reducing viable methicillin-resistant staphylococcus aureus in infectious keratitis. Cornea 39(2):250–253
Flynn HW, Batra NR, Schwartz SG, Grzybowski A. (2018) Antimicrobial treatment: routes/dosages/preparation/adverse effects, antimicrobial resistance, and alternatives. Endophthalmitis in clinical practice, Springer, pp 123–139
Ong SJ, Huang YC, Tan HY et al (2013) Staphylococcus aureus keratitis: a review of hospital cases. PLoS ONE 8(11):e80119
Cong Y, Yang S, Rao X (2020) Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features. J Adv Res 21:169–176
Liu CY, Lee WS, Fung CP et al (1996) Comparative study of teicoplanin vs vancomycin for the treatment of methicillin-resistant staphylococcus aureus bacteraemia. Clin Drug Investig 12(2):80–87
Svetitsky S, Leibovici L, Paul M (2009) Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 53(10):4069–4079
Torumkuney D, Tunger A, Sancak B et al (2020) Results from the Survey of antibiotic resistance (SOAR) 2015–17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 75(Supplement_1):i88–i99
Parks RW, Clements WD, Smye MG, Pope C, Rowlands BJ, Diamond T (1996) Intestinal barrier dysfunction in clinical and experimental obstructive jaundice and its reversal by internal biliary drainage. Br J Surg 83(10):1345–1349
Mengeloglu FZ, Kucukbayrak A, Bucak YY et al (2013) Efficacy of daptomycin on experimental methicillin-resistant Staphylococcus aureus keratitis in rabbits. J Ocul Pharmacol Ther 29(10):893–899
Akova Budak B, Baykara M, Kivanc SA, Yilmaz H, Cicek S (2016) Comparing the ocular surface effects of topical vancomycin and linezolid for treating bacterial keratitis. Cutan Ocul Toxicol 35(2):126–130
Goktas S, Kurtoglu MG, Sakarya Y et al (2015) New therapy option for treatment of methicillin-resistant Staphylococcus aureus keratitis: tigecycline. J Ocul Pharmacol Ther 31(2):122–127
Sueke H, Kaye SB, Neal T, Hall A, Tuft S, Parry CM (2010) An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. Invest Ophthalmol Vis Sci 51(8):4151–4155
Kaye SB, Neal T, Nicholson S et al (2009) Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea. Invest Ophthalmol Vis Sci 50(7):3176–3184
Briggs MC, McDonald P, Bourke R, Smith G, McGalliard JN, Wong D (1998) Intravitreal penetration of teicoplanin. Eye (Lond) 12(Pt 2):252–255
Irigoyen C, Ziahosseini K, Morphis G, Stappler T, Heimann H (2012) Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 250(4):499–505
Gupta AA, Mammo DA, Page MA (2020) Intrastromal bevacizumab in the management of corneal neovascularization: a retrospective review. Graefes Arch Clin Exp Ophthalmol 258(1):167–173
Nada WM, Al Aswad MA, El-Haig WM (2017) Combined intrastromal injection of amphotericin B and topical fluconazole in the treatment of resistant cases of keratomycosis: a retrospective study. Clin Ophthalmol 11:871–874
Liang SY, Lee GA (2011) Intrastromal injection of antibiotic agent in the management of recalcitrant bacterial keratitis. J Cataract Refract Surg 37(5):960–962
Feng HL, Robbins CB, Fekrat S (2020) A nine-year analysis of practice patterns, microbiologic yield, and clinical outcomes in cases of presumed infectious endophthalmitis. Ophthalmol Retina 4(6):555–559
Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ (2003) In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 47(7):2334–2338
Fleischer AB, Hoover DL, Khan JA, Parisi JT, Burns RP (1986) Topical vancomycin formulation for methicillin-resistant Staphylococcus epidermidis blepharoconjunctivitis. Am J Ophthalmol 101(3):283–287
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Contributions
AYU and MB designed and conducted the study. MB made substantial contributions to acquisition of microbiological data. AYU wrote the manuscript. Two authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethical approval
The Animal Experiments Local Ethics Committee at the University of Abant Izzet Baysal (Bolu, Turkey) approved the study (Approval No: 2019/41).
Plant reproducibility
Not applicable.
Clinical trials registration
None.
Gels and blots/image manipulation
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ucgul, A.Y., Behcet, M. Comparison of the effect of teicoplanin and vancomycin on experimental methicillin-resistant staphylococcus aureus keratitis. Int Ophthalmol 41, 1395–1402 (2021). https://doi.org/10.1007/s10792-021-01696-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-021-01696-2